Janssen, the pharmaceutical companies of Johnson & Johnson, has
launched a first-of-its-kind paediatric HIV treatment donation programme
to improve access to the company's approved HIV medicines for children
and adolescents failing HIV treatment in sub-Saharan Africa.
At a symposium entitled When Children Need HIV Treatment Beyond First-Line: How Can We All Respond? at the 17th International Conference on AIDS and STIs in Africa (ICASA), Ministries of Health (MOHs) in sub-Saharan Africa were invited to submit a formal Expression of Interest to participate in the charitable paediatric HIV treatment donation programme.
Through this programme, Janssen will donate its HIV medicines PREZISTA (darunavir) and INTELENCE (etravirine), including child-friendly formulations, free of charge to eligible countries with the clinical capacity and willingness to address second- and third-line paediatric HIV treatment. Each child enrolled will receive Janssen's donated HIV medicines as needed until they turn 19 at which point they will be transitioned into the adult national HIV programme or other designated by the national HIV programme for continued treatment.
The donation programme is intended to be a first step in a broader collaborative effort to build awareness, incite action, and advance learning around second- and third-line paediatric HIV treatment in sub-Saharan Africa. Janssen is working with the Elizabeth Glaser Paediatric AIDS Foundation, the Partnership for Supply Chain Management (PFSCM), and MAP International to fully maximize the impact and reach of this initiative.
"The donation programme is part of our longstanding commitment to help people living with HIV and enhance access to our medicines for those in need. Only a third of the three million children living with HIV are receiving medicines today, and of those children receiving treatment, a small but growing number are experiencing HIV treatment failures and are in need of new treatment options," said Paul Stoffels, MD, chief scientific officer, Johnson & Johnson and worldwide chairman, Janssen. "We hope this innovative donation programme is the first step in sparking further collaborative action across sub-Saharan Africa for children who are experiencing HIV treatment failure. Our vision is that these children receive the HIV treatment and care they need to stay healthy and grow to become healthy, productive young adults."
At a symposium entitled When Children Need HIV Treatment Beyond First-Line: How Can We All Respond? at the 17th International Conference on AIDS and STIs in Africa (ICASA), Ministries of Health (MOHs) in sub-Saharan Africa were invited to submit a formal Expression of Interest to participate in the charitable paediatric HIV treatment donation programme.
Through this programme, Janssen will donate its HIV medicines PREZISTA (darunavir) and INTELENCE (etravirine), including child-friendly formulations, free of charge to eligible countries with the clinical capacity and willingness to address second- and third-line paediatric HIV treatment. Each child enrolled will receive Janssen's donated HIV medicines as needed until they turn 19 at which point they will be transitioned into the adult national HIV programme or other designated by the national HIV programme for continued treatment.
The donation programme is intended to be a first step in a broader collaborative effort to build awareness, incite action, and advance learning around second- and third-line paediatric HIV treatment in sub-Saharan Africa. Janssen is working with the Elizabeth Glaser Paediatric AIDS Foundation, the Partnership for Supply Chain Management (PFSCM), and MAP International to fully maximize the impact and reach of this initiative.
"The donation programme is part of our longstanding commitment to help people living with HIV and enhance access to our medicines for those in need. Only a third of the three million children living with HIV are receiving medicines today, and of those children receiving treatment, a small but growing number are experiencing HIV treatment failures and are in need of new treatment options," said Paul Stoffels, MD, chief scientific officer, Johnson & Johnson and worldwide chairman, Janssen. "We hope this innovative donation programme is the first step in sparking further collaborative action across sub-Saharan Africa for children who are experiencing HIV treatment failure. Our vision is that these children receive the HIV treatment and care they need to stay healthy and grow to become healthy, productive young adults."
No comments:
Post a Comment